How Seed Stage Biotech Navigate BD Engagement

• Discussing unique constraints of seed-stage companies when approaching BD engagement
• Maintaining relationships with big pharma and VCs when data is early and limited
• Outlining opportunities for creative deal structures, and when and where they would be appropriate

Speakers:

Yaron Sfadyah

Chief Executive Officer

Coltac Therapeutics

Adam Gilbert

Science Partner

Flagship Pioneering

Nicki Thompson

Chief Executive Officer

Trimtech Therapeutics

Giovanni Spagnolli

Co-Founder & Chief Technology Officer

Sibylla Biotech srl